P3.01-084 Analysis on ALTER0303 Trial: ACECs Level May Correlate With Metastases Burden and Predict PFS of Anlotinib in Advanced NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2017.09.1525
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.01-01 the Impact of Anlotinib on Brain Metastases of NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-107 the Impact of Anlotinib on Quality of Life in Patients With Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-116 Randomized Clinical Trial on Three Different Platinum Based Chemotherapy in Advanced NSCLC in Bangladeshi Population

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

MA05.09 PFS and Cardiac-Toxicity-Adjusted-PFS as Predictors of OS in Locally Advanced NSCLC Treated With Concurrent Chemoradiation

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line

Frontiers in Oncology
Cancer ResearchOncology
2019English

P3.01-20 Advanced NSCLC Treatment and Outcomes After Nivolumab

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-79 Intracerebral Efficacy of Immune Check-Point Inhibitors in NSCLC Patients With Brain Metastases

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P3.01-68 Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients With Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Cost Analysis of the Management of Brain Metastases in Patients With Advanced ALK+ NSCLC: Alectinib Versus Crizotinib

Lung Cancer Management
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy